Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
?

?

-1.330%
-0.06
-1.330%
-
 
09:33 / Stuttgart Stock Exchange WKN: A2PZG1 / Name: Precigen / Stock / Electrical Utilities & IPPs / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Precigen Inc. Stock

A loss of -1.330% shows a downward development for Precigen Inc..

Pros and Cons of Precigen Inc. in the next few years

Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Precigen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Precigen Inc. -1.330% -6.250% 17.801% 171.411% 21.228% 336.893% -8.276%
Mighty River Power Ltd 0.000% 0.000% -5.917% 3.247% 1.923% -11.173% -16.316%
A2A SpA -0.250% 1.463% 3.740% 6.649% 2.656% 41.749% 35.634%
CEMIG ADR 0.530% 1.648% 3.352% 17.089% 8.187% -18.142% 27.921%

News

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing.

Transaction value

Precigen Q1 Earnings Call Highlights
Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025